Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): Crossover pilot study (J-VICTORIA study)

Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): Crossover pilot study (J-VICTORIA study)

<p>Abstract</p> <p>Background</p> <p>No previous studies have compared the DPP-4 inhibitors vildagliptin and sitagliptin in terms of blood glucose levels using continuous glucose monitoring (CGM) and cardiovascular parameters.</p> <p>Methods</p> <p&...

Full description

Bibliographic Details
Main Authors: Sakamoto Masaya, Nishimura Rimei, Irako Taiga, Tsujino Daisuke, Ando Kiyotaka, Utsunomiya Kazunori
Format: Article
Language:English
Published: BMC 2012-08-01
Series:Cardiovascular Diabetology
Subjects:
Vildagliptin
Sitagliptin
Continuous glucose monitoring (CGM)
Brain natriuretic peptide (BNP)
Plasminogen activator inhibitor-1 (PAI-1)
Online Access:http://www.cardiab.com/content/11/1/92

Internet

http://www.cardiab.com/content/11/1/92

Similar Items